KRAS mutation status is reported to be an important prognostic and treatment marker in CRC, and screening for KRAS mutations is now mandatory for metastatic colon cancer before treatment with therapies that target the EGFR pathway (15–17). This evidence concerns the gene KRAS and colorectal carcinoma.